Loomis Sayles & Co. L P Raises Position in HealthEquity, Inc. (NASDAQ:HQY)

Loomis Sayles & Co. L P lifted its position in HealthEquity, Inc. (NASDAQ:HQY) by 2.2% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 1,126,645 shares of the company’s stock after acquiring an additional 24,665 shares during the period. Loomis Sayles & Co. L P’s holdings in HealthEquity were worth $92,216,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. O Shaughnessy Asset Management LLC lifted its stake in HealthEquity by 3.9% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 5,219 shares of the company’s stock valued at $426,000 after acquiring an additional 197 shares during the period. Bessemer Group Inc. lifted its position in HealthEquity by 19.2% during the first quarter. Bessemer Group Inc. now owns 2,838 shares of the company’s stock valued at $231,000 after purchasing an additional 457 shares during the period. CANADA LIFE ASSURANCE Co boosted its holdings in HealthEquity by 2.1% in the first quarter. CANADA LIFE ASSURANCE Co now owns 65,666 shares of the company’s stock worth $5,360,000 after purchasing an additional 1,344 shares during the last quarter. Shell Asset Management Co. purchased a new stake in HealthEquity in the first quarter worth approximately $233,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of HealthEquity by 7.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 51,384 shares of the company’s stock worth $4,195,000 after acquiring an additional 3,365 shares during the period. Hedge funds and other institutional investors own 99.55% of the company’s stock.

HealthEquity Stock Performance

Shares of NASDAQ:HQY opened at $104.25 on Monday. The firm’s 50 day simple moving average is $87.74 and its 200-day simple moving average is $81.95. The firm has a market cap of $9.10 billion, a PE ratio of 86.88, a price-to-earnings-growth ratio of 1.63 and a beta of 0.52. HealthEquity, Inc. has a one year low of $62.10 and a one year high of $105.73. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.10 and a current ratio of 4.10.

HealthEquity (NASDAQ:HQY) last posted its earnings results on Tuesday, September 3rd. The company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.50 by $0.16. The business had revenue of $299.93 million for the quarter, compared to the consensus estimate of $284.48 million. HealthEquity had a net margin of 9.61% and a return on equity of 9.01%. As a group, equities analysts predict that HealthEquity, Inc. will post 2.27 EPS for the current year.

Insider Buying and Selling

In related news, Director Frank Corvino sold 1,039 shares of the company’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $96.10, for a total transaction of $99,847.90. Following the transaction, the director now directly owns 3,784 shares of the company’s stock, valued at $363,642.40. This represents a 21.54 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Robert W. Selander sold 8,250 shares of the business’s stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total transaction of $684,585.00. Following the sale, the director now directly owns 54,719 shares in the company, valued at approximately $4,540,582.62. This represents a 13.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,536 shares of company stock worth $884,517 in the last three months. 2.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on HQY shares. Bank of America lifted their price target on shares of HealthEquity from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. The Goldman Sachs Group began coverage on shares of HealthEquity in a report on Friday, November 15th. They set a “neutral” rating and a $108.00 price objective for the company. BTIG Research lifted their target price on HealthEquity from $110.00 to $130.00 and gave the stock a “buy” rating in a report on Thursday, November 14th. Barrington Research reaffirmed an “outperform” rating and set a $105.00 price target on shares of HealthEquity in a research note on Friday, September 20th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $92.00 target price on shares of HealthEquity in a report on Wednesday, September 4th. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $107.23.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.